Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rejuviel v + lidocaine
- Development stage
- Unknown
- Lead developer
- PharmaResearch
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Rejuviel V + lidocaine is a combination dermal filler product consisting of cross-linked hyaluronic acid (sodium hyaluronate) and lidocaine. It is injected into the subcutaneous layer to temporarily improve facial wrinkles through physical restoration. Hyaluronic acid provides volume and hydration, supporting tissue structure, while lidocaine acts as a local anesthetic to reduce pain during injection[1][4][7][9]. The product is classified as a medical device and is primarily intended for cosmetic procedures, specifically facial wrinkle correction.
- Other names
- rejuviel v with lidocaine
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on rejuviel v + lidocaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rejuviel v + lidocaine.